AtheroNova Receives Notice of Issuance of Its U.S. Patent 8,304,383
IRVINE, Calif., Nov. 15, 2012 /PRNewswire/ -- AtheroNova Inc.
(OTCBB: AHRO), a biotech company focused on the research and
development of compounds to safely regress atherosclerotic plaque
and to improve lipid profiles in humans, today announced that it
has received a Notice of Issuance for its patent application for
Dissolution of Arterial Plaque. This patent issuance is the
first major step in the development of the Company's intellectual
property involving lipid modulation and reduction. This
issuance culminates a major effort by the Company and its patent
counsel in pursuit of a patent covering the use of hyodeoxycholic
acid for atherosclerotic plaque lesions.
"This patent issuance is a tremendous milestone for the
Company," said AtheroNova CEO Thomas W.
Gardner. "We are very confident that this patent will
support our development project for AHRO-001 as we move toward the
next phase of entering human clinical trials. The Company's
partner, OOO CardioNova, has completed a similar intellectual
property filing on behalf of AtheroNova in the Eurasian markets and
they expect action on these filings to be moving forward in the
near future."
About AHRO-001
AHRO-001 is AtheroNova's first novel application for the
treatment and prevention of atherosclerosis. Atherosclerotic plaque
is the primary, underlying cause of heart disease and stroke in
industrialized countries. AHRO-001 uses certain pharmacological
compounds to regress atherosclerotic plaque deposits through a
process known as delipidization. Delipidization dissolves plaques
in artery walls, which are then removed by natural body processes.
AtheroNova is developing, and seeks to eventually market AHRO-001,
a product that has the potential to become a new standard of care
for patients prone to atherosclerotic plaque accumulation.
About AtheroNova
AtheroNova Inc., through its wholly-owned subsidiary, AtheroNova
Operations, Inc., is a biotechnology company focused on the
discovery, research, development and licensing of novel compounds
to reduce or regress atherosclerotic plaque deposits and to safely
improve lipid profiles in humans. In addition to its lead compound
AHRO-001, AtheroNova plans to develop multiple applications for its
patents-pending therapies in market sectors that include:
Cardiovascular Disease, Stroke, Peripheral Artery Disease, Dementia
and Alzheimer's and Erectile Dysfunction, all of which have been
linked to atherosclerosis. Atherosclerosis and its related
pharmaceutical expenses for these indications cost consumers more
than $41 billion annually in
the United States alone. For more
information, please visit www.AtheroNova.com.
Forward-Looking Statements
Except for historical information contained herein, the
statements in this release are forward-looking and made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are inherently
unreliable and actual results may differ materially. Examples of
forward-looking statements in this news release include statements
regarding the suitability of the compound for its intended use,
mechanisms of action, intellectual property as well as the
development of applications for AtheroNova's technology. Factors
which could cause actual results to differ materially from these
forward-looking statements include such factors as significant
fluctuations in expenses associated with clinical trials, failure
to secure additional financing, the inability to complete
regulatory filings with the Food and Drug Administration, the
introduction of competing products, or management's ability to
attract and maintain qualified personnel necessary for the
development and commercialization of its planned products, and
other information that may be detailed from time to time in
AtheroNova's filings with the United States Securities and Exchange
Commission. AtheroNova undertakes no obligation to publicly update
or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.
SOURCE AtheroNova Inc.